MX2007013133A - Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b. - Google Patents

Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b.

Info

Publication number
MX2007013133A
MX2007013133A MX2007013133A MX2007013133A MX2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A
Authority
MX
Mexico
Prior art keywords
apo
secretion
compounds
inhibitors
transfer protein
Prior art date
Application number
MX2007013133A
Other languages
English (en)
Inventor
Yingfei Yang
Alessandra Bartolozzi
A Campbell
Hope Foudoulakis
Enoch Kim
Paul Sweetnam
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of MX2007013133A publication Critical patent/MX2007013133A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con compuestos los cuales son inhibidores de la proteina microsomal de transferencia de trigliceridos y/o de la secrecion de apolipoproteina B (Apo B). Estos compuestos pueden ser utiles para la prevencion y tratamiento de diversas enfermedades, particularmente ateroesclerosis y sus secuelas clinicas, para disminuir lipidos sericos y afecciones relacionadas. La invencion ademas se relaciona con composiciones farmaceuticas que comprenden los compuestos y con metodos para tratar enfermedades, tales como hipertrigliceridemia, hiperquilomicronemia, ateroesclerosis, obesidad y padecimientos relacionados utilizando los compuestos. Tambien se proporciona un metodo para disminuir la secrecion de apolipoproteina B (apo B).
MX2007013133A 2005-04-19 2006-04-19 Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b. MX2007013133A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67277805P 2005-04-19 2005-04-19
US75539005P 2005-12-30 2005-12-30
PCT/US2006/015146 WO2006113910A2 (en) 2005-04-19 2006-04-19 Inhibitors of microsomal triglyceride transfer protein and apo-b secretion

Publications (1)

Publication Number Publication Date
MX2007013133A true MX2007013133A (es) 2008-03-14

Family

ID=37115969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013133A MX2007013133A (es) 2005-04-19 2006-04-19 Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b.

Country Status (19)

Country Link
US (2) US8980915B2 (es)
EP (1) EP1877369B1 (es)
JP (1) JP5356017B2 (es)
KR (1) KR20080015792A (es)
AU (1) AU2006236226B2 (es)
BR (1) BRPI0607555A2 (es)
CA (1) CA2605510C (es)
CR (1) CR9528A (es)
EA (1) EA024768B1 (es)
EC (1) ECSP077913A (es)
ES (1) ES2430319T3 (es)
GE (1) GEP20104878B (es)
IL (1) IL186820A0 (es)
MX (1) MX2007013133A (es)
NI (1) NI200700272A (es)
NO (1) NO20075731L (es)
NZ (1) NZ563009A (es)
SG (1) SG164371A1 (es)
WO (1) WO2006113910A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605510C (en) 2005-04-19 2013-12-24 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
US8163708B2 (en) 2006-04-03 2012-04-24 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotide
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA019939B1 (ru) 2007-10-04 2014-07-30 Сантарис Фарма А/С МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
SI3013959T1 (sl) 2013-06-27 2020-04-30 Roche Innovation Center Copenhagen A/S Protismiselni oligomeri in konjugati, ki ciljajo PCSK9
US20230321073A1 (en) * 2020-08-06 2023-10-12 Response IP Holding Company, LLC Compositions and methods for treating metabolic dysregulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69110828T2 (de) * 1990-10-16 1995-11-30 Takeda Chemical Industries Ltd Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP1181954A3 (en) * 1995-06-07 2002-08-21 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
ATE233734T1 (de) * 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
NZ330216A (en) 1996-01-16 2000-09-29 Bristol Myers Squibb Co Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis
JP3270764B2 (ja) 1996-11-27 2002-04-02 ファイザー・インク アポｂ−分泌／ｍｔｐ阻害性アミド
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
WO2001053260A1 (en) 2000-01-18 2001-07-26 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
WO2001077077A1 (en) 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
CA2468716A1 (en) * 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
JP2003231633A (ja) 2002-02-06 2003-08-19 Tanabe Seiyaku Co Ltd 医薬組成物
EA010369B1 (ru) * 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
CA2605510C (en) 2005-04-19 2013-12-24 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and apo-b secretion

Also Published As

Publication number Publication date
NZ563009A (en) 2011-05-27
US8980915B2 (en) 2015-03-17
WO2006113910A2 (en) 2006-10-26
US9656960B2 (en) 2017-05-23
KR20080015792A (ko) 2008-02-20
IL186820A0 (en) 2008-02-09
GEP20104878B (en) 2010-01-11
NO20075731L (no) 2008-01-17
EP1877369B1 (en) 2013-07-10
WO2006113910A3 (en) 2007-03-22
AU2006236226B2 (en) 2012-07-05
BRPI0607555A2 (pt) 2009-09-15
CR9528A (es) 2008-05-21
US20070027183A1 (en) 2007-02-01
CA2605510C (en) 2013-12-24
ES2430319T3 (es) 2013-11-20
EA024768B1 (ru) 2016-10-31
SG164371A1 (en) 2010-09-29
CA2605510A1 (en) 2006-10-26
EA200702271A1 (ru) 2008-04-28
JP2008538568A (ja) 2008-10-30
EP1877369A4 (en) 2010-04-14
NI200700272A (es) 2008-07-11
JP5356017B2 (ja) 2013-12-04
AU2006236226A1 (en) 2006-10-26
EP1877369A2 (en) 2008-01-16
ECSP077913A (es) 2008-01-23
US20160039765A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
SG164371A1 (en) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
WO2008033562A3 (en) Kinase inhibitor compounds
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
NO20063928L (no) Substituerte kinolinforbindelser
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
WO2008127682A3 (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
PL377713A1 (pl) Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
EA200801008A1 (ru) Гипохолестеринемические соединения
BR0317323A (pt) Inibidores de proteìna de transferência de triglicerìdeos microssomal
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
BR0317426A (pt) Inibidores de proteìna de transferência de triglicéridos microssomais
EA200700479A1 (ru) Соединения 4-аминозамещённого-2-замещённого-1,2,3,4-тетрагидрохинолина
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal